Identification of the interaction network of hub genes for melanoma treated with vemurafenib based on microarray data

Liangliang Quan1, Yang Wang, Jiulong Liang

  • 1Department of Plastic Surgery, General Hospital of Shenyang Military Area Command, PLA, Liaoning - China.

Tumori
|May 19, 2015
PubMed
Abstract

Insights

Vemurafenib suppresses melanoma progression by impacting cell cycle and focal adhesion pathways. Key genes identified include Cell division cycle 6, CHEK1, E2F1, EGFR, and PIK3R1, offering potential therapeutic targets.

Area of Science:

  • Genomics and Bioinformatics
  • Melanoma Research
  • Molecular Biology

Background:

  • Melanoma is a significant skin cancer with complex progression mechanisms.
  • Vemurafenib is a targeted therapy for melanoma, but its precise suppression mechanisms require further elucidation.

Purpose of the Study:

  • To identify potential biomarkers for vemurafenib's effect on melanoma.
  • To explore the molecular mechanisms underlying vemurafenib's suppression of melanoma progression.

Main Methods:

  • Analysis of Gene Expression Omnibus (GEO) dataset GSE42872 using affymetrix microarray data.
  • Identification of differentially expressed genes (DEGs) between vemurafenib-treated and vehicle-treated melanoma samples.
  • Gene Ontology, pathway enrichment, and protein-protein interaction (PPI) network analyses, including BioNet screening and KEGG pathway analysis.

Main Results:

  • Identified 794 upregulated and 977 downregulated transcripts.
  • Downregulated DEGs were enriched in cell cycle, DNA replication, and p53 signaling pathways.
  • Upregulated DEGs were enriched in phosphatidylinositol signaling and inositol phosphate metabolism pathways.
  • Key genes within a significant module (Cell division cycle 6, CHEK1, E2F1, EGFR, PIK3R1) were associated with cell cycle, apoptosis, focal adhesion, and DNA replication pathways.

Conclusions:

  • Cell division cycle 6, CHEK1, E2F1, EGFR, and PIK3R1, along with cell cycle and focal adhesion pathways, are implicated in vemurafenib's suppression of melanoma progression.
  • These findings suggest potential therapeutic targets and mechanistic insights for vemurafenib therapy in melanoma.

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.2K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

3.1K
DNA Microarrays02:34

DNA Microarrays

Microarrays are high-throughput and relatively inexpensive assays that can be automated to analyze large quantities of data at a time. They are used in genome-wide studies to compare gene or protein expression under two varied conditions, such as healthy and diseased states. Microarrays consist of glass or silica slides on which probe molecules are covalently attached through surface functionalization. Most commonly, the slides are prepared through the chemisorption of silanes to silica...
23.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K